Project Grant R43EY037173
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $300K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This $305,321 Project Grant awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports the clinical development and commercialization of a topical ophthalmic treatment for neovascular age-related macular degeneration (NAMD). The funding will enable the awardee, Neovascularx, Inc., to advance their AMD101 (rifampicin) compound, which aims to provide a less invasive, home-based alternative to the current standard of care intravitreous injections for...
- This $440,000 Project Grant award from the National Eye Institute (NEI), under Federal Grant Program 93.867 (Vision Research), aims to develop a novel, disease-targeted anti-angiogenic therapy for treating wet age-related macular degeneration (AMD). The key product being developed is a neutralizing monoclonal antibody that targets a new, CNV-selective angiogenic factor discovered through the awardee's comparative ligandomics technology. This approach differs from currently approved anti-VEGF...
- The National Eye Institute (NEI) awarded a $312,239 Project Grant under the Vision Research federal grant program (CFDA 93.867) to Shift Pharmaceuticals Holdings, Inc. for the development of an antisense oligonucleotide (ASO) therapeutic to inhibit retinoic acid signaling and mitigate vision loss in retinitis pigmentosa and age-related macular degeneration. The project aims to create a targeted ASO therapy that can block the production of retinoic acid receptors at the cellular level within...
- The National Eye Institute (NEI) awarded a $173,016 Project Grant to the Whitehead Institute for Biomedical Research to conduct research on identifying and characterizing novel oxidative protective genes that can prevent retinal pigment epithelium (RPE) degeneration, a key cause of age-related macular degeneration (AMD). The research project, titled "Systematic Identification and Mechanistic Characterization of Novel Oxidative Protective Genes to Prevent RPE Degeneration", aims to...
- This Project Grant award of $310,952 from the National Eye Institute's Vision Research program, awarded on August 1, 2025, supports the development of a novel gene therapy approach by Bedrock Therapeutics, Inc., a small disadvantaged biotech company located in Raleigh, North Carolina. The goal is to create an effective and practical treatment for neovascular age-related macular degeneration (NAMD), the leading cause of blindness in people over 50. Bedrock's strategy combines an...
- This $244,379 Project Grant award from the National Eye Institute's Vision Research program (CFDA 93.867) supports research at the University of California, Los Angeles (UCLA) to explore how genetic variation influences disease progression and treatment response in age-related macular degeneration (AMD), a leading cause of vision loss. The project aims to leverage machine learning (ML) and artificial intelligence (AI) techniques to analyze optical coherence tomography (OCT) imaging data and...
- This federal Project Grant award of $240,713 from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports research into the role of the nuclear-encoded humanin isoform MTRNR2L1 in age-related macular degeneration (AMD). The awardee, The Research Foundation for the State University of New York (RF SUNY), will investigate whether MTRNR2L1 is a protein-coding gene or a long non-coding RNA, and examine its function in regulating mitochondrial activity and cell...
- This $1,813,621 Project Grant was awarded by the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) to support a research project titled "Nutritional Metabolomics in Age-Related Macular Degeneration and Retinal Integrity". The grant, awarded to The Research Foundation For The State University Of New York (RF SUNY), will fund the analysis of approximately 2,000 metabolites from participant serum samples to examine the relationship between...
- This $638,625 Project Grant awarded by the National Eye Institute (CFDA 93.867 - Vision Research) to the University of California, San Diego (UC San Diego) aims to investigate the mechanism of drusen formation in age-related macular degeneration (AMD). The research will utilize a novel Bruch's membrane-on-a-chip assay developed by the university to study the retention of lipoproteins in the extracellular matrix, which is believed to contribute to drusen accumulation in the early and intermediate...
- This federal Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) is providing $658,889 to the University of Rochester to investigate the role of the secretory phospholipase A2-IIA (PLA2G2A/sPLA2-IIA) enzyme in the development of age-related macular degeneration (AMD). The research aims to critically evaluate the pathogenic role of PLA2G2A in AMD using human donor eyes, patient-derived induced pluripotent stem cells, and transgenic mouse models. The ultimate goal...